As of 2024-09-20, the EV/EBITDA ratio of Myriad Genetics Inc (MYGN) is -58.08. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MYGN's latest enterprise value is 2,456.66 mil USD. MYGN's TTM EBITDA according to its financial statements is -42.30 mil USD. Dividing these 2 quantities gives us the above MYGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.8x - 13.9x | 12.4x |
| Forward P/E multiples | 11.5x - 16.9x | 14.8x |
| Fair Price | (4.78) - (5.87) | (5.72) |
| Upside | -117.3% - -121.3% | -120.7% |
| Date | EV/EBITDA |
| 2024-09-20 | -58.08 |
| 2024-09-19 | -59.47 |
| 2024-09-18 | -59.86 |
| 2024-09-17 | -60.14 |
| 2024-09-16 | -58.64 |
| 2024-09-13 | -57.97 |
| 2024-09-12 | -55.39 |
| 2024-09-11 | -55.16 |
| 2024-09-10 | -56.79 |
| 2024-09-09 | -57.00 |
| 2024-09-06 | -56.64 |
| 2024-09-05 | -58.12 |
| 2024-09-04 | -53.18 |
| 2024-09-03 | -57.69 |
| 2024-08-30 | -59.56 |
| 2024-08-29 | -59.54 |
| 2024-08-28 | -58.72 |
| 2024-08-27 | -57.78 |
| 2024-08-26 | -58.10 |
| 2024-08-23 | -59.11 |
| 2024-08-22 | -58.12 |
| 2024-08-21 | -58.70 |
| 2024-08-20 | -58.08 |
| 2024-08-19 | -59.41 |
| 2024-08-16 | -59.24 |
| 2024-08-15 | -58.53 |
| 2024-08-14 | -58.01 |
| 2024-08-13 | -59.24 |
| 2024-08-12 | -58.74 |
| 2024-08-09 | -58.74 |
| 2024-08-08 | -58.14 |
| 2024-08-07 | -55.93 |
| 2024-08-06 | -54.47 |
| 2024-08-05 | -54.21 |
| 2024-08-02 | -55.95 |
| 2024-08-01 | -57.99 |
| 2024-07-31 | -58.79 |
| 2024-07-30 | -58.44 |
| 2024-07-29 | -57.41 |
| 2024-07-26 | -58.10 |
| 2024-07-25 | -58.53 |
| 2024-07-24 | -58.89 |
| 2024-07-23 | -58.87 |
| 2024-07-22 | -58.31 |
| 2024-07-19 | -54.49 |
| 2024-07-18 | -55.87 |
| 2024-07-17 | -56.90 |
| 2024-07-16 | -57.54 |
| 2024-07-15 | -55.93 |
| 2024-07-12 | -55.46 |